知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

98 records (took 0.049 seconds)

    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
    3.
    发明申请
    NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT 审中-公开
    包含其中的核酸（NuGlXmGnNv）及其衍生物作为免疫抑制剂/调节剂

    公开(公告)号：US20160250321A1

    公开(公告)日：2016-09-01

    申请号：US14954363

    申请日：2015-11-30

    Applicant: CureVac AG

    Inventor： Thomas KRAMPS ,  Söhnke VOSS ,  Jochen PROBST ,  Ingmar HOERR

    IPC: A61K39/39 ,  C12N15/117

    CPC classification number: A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/487

    Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

    Abstract translation: 本发明涉及通式（I）的核酸：（NuG1XmGnNv）a及其衍生物作为免疫刺激剂/佐剂和含有其的组合物，任选地包含另外的佐剂。 本发明还涉及药物组合物或疫苗，其各自含有上述式（I）核酸和/或其衍生物作为免疫刺激剂，以及任选的至少一种另外的药物活性成分，例如， 抗原剂。 本发明同样涉及药物组合物或疫苗用于治疗癌症疾病，感染性疾病，过敏症和自身免疫疾病等的用途。同样地，本发明包括通式（I）的核酸， ：（NuGlXmGnNv）a和/或其衍生物，用于制备用于治疗这些疾病的药物组合物。

    METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTORS AND ADAPTORS THEREOF
    5.
    发明申请
    METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTORS AND ADAPTORS THEREOF 审中-公开
    通过诱导CD40和模式识别受体及其适配体产生免疫应答的方法和组合物

    公开(公告)号：US20140287490A1

    公开(公告)日：2014-09-25

    申请号：US14191167

    申请日：2014-02-26

    Applicant: BAYLOR COLLEGE OF MEDICINE

    Inventor： David SPENCER ,  Natalia Lapteva

    IPC: C07K14/705 ,  C12N9/14

    CPC classification number: C07K14/70578 ,  A61K2039/57 ,  C07K14/705 ,  C12N9/14 ,  C12N2510/00 ,  Y02A50/487

    Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing pattern recognition receptor activity, and CD40 activity. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing CD40 activity without prostaglandin E2. Also provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible chimeric molecule comprising a region of a pattern recognition receptor or an adaptor thereof.

    Abstract translation: 提供了通过诱导模式识别受体活性和CD40活性激活抗原呈递细胞并引发免疫应答的方法。 还提供了激活抗原呈递细胞并通过在没有前列腺素E2的情况下诱导CD40活性引发免疫应答的方法。 还提供了通过诱导包含图案识别受体或其适配体的区域的诱导型嵌合分子来激活抗原呈递细胞并引发免疫应答的方法。

    STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
    6.
    发明申请
    STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS 审中-公开
    稳定HBc CHIMER颗粒作为治疗用于慢性乙型肝炎的疫苗

    公开(公告)号：US20100183652A1

    公开(公告)日：2010-07-22

    申请号：US12049097

    申请日：2008-03-14

    Applicant: Mark Page ,  Martin Friede ,  Annette Elisabeth Schmidt ,  Detlef Stober

    Inventor： Mark Page ,  Martin Friede ,  Annette Elisabeth Schmidt ,  Detlef Stober

    IPC: A61K39/29

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/5258 ,  A61K2039/55555 ,  A61K2039/55566 ,  C07K2319/00 ,  C12N2730/10122 ,  C12N2730/10134 ,  Y02A50/412 ,  Y02A50/414 ,  Y02A50/423 ,  Y02A50/476 ,  Y02A50/487 ,  Y02A50/489

    Abstract: A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.

    Abstract translation: 公开了一种治疗慢性乙型肝炎的方法，其包括向患者施用T细胞刺激量的疫苗。 疫苗包含免疫原性量的嵌合，羧基末端截短的乙型肝炎病毒核衣壳（核心）蛋白（核心）蛋白（HBc），其被设计用于增强自组装颗粒的稳定性和基本上不存在由这些颗粒结合的核酸。 嵌合蛋白分子可以包括与HBc的一个或多个N末端，免疫原性环或C末端肽结合的一个或多个免疫原性表位。 通过在嵌合体分子的氨基末端和羧基末端的一个或两个附近存在至少一个异源半胱氨酸残基获得自组装颗粒的增强的稳定性。

    Anti-Inflammatory Proteins and Improved Vaccines
    8.
    发明申请
    Anti-Inflammatory Proteins and Improved Vaccines 审中-公开
    抗炎蛋白和改进疫苗

    公开(公告)号：US20090110694A1

    公开(公告)日：2009-04-30

    申请号：US12225456

    申请日：2007-03-22

    Applicant: Geoffrey Smith ,  An-Jung Chen

    Inventor： Geoffrey Smith ,  An-Jung Chen

    IPC: A61K39/12 ,  C12N7/00 ,  C12N15/11 ,  C07K2/00 ,  A61K38/02 ,  A61K31/7088 ,  C12N5/06

    CPC classification number: C12N15/86 ,  A61K39/00 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/24122 ,  C12N2710/24143 ,  C12N2710/24161 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/476 ,  Y02A50/487

    Abstract: A recombinant poxvirus lacking a functional gene corresponding to BI4R in the WR strain of VACV for use as a medicament especially as a vaccine against a disease caused by a poxvirus or another pathogenic agent or for use as a medicament against a disease associated with aberrant cells. An isolated nucleotide or polypeptide encoding a poxvirus sequence corresponding to the sequence of B14 in the WR strain of VACV especially for use as a medicament against undesirable inflammation, immune activation or NF-κB activation. Related compositions and methods.

    Abstract translation: 在VACV的WR菌株中缺乏与BI4R相对应的功能基因的重组痘病毒用作药物，特别是作为针对由痘病毒或另一病原体引起的疾病的疫苗或用作抗异常细胞相关疾病的药物。 编码对应于VACV的WR菌株中的B14序列的痘病毒序列的分离的核苷酸或多肽，特别是用作抗不需要的炎症，免疫激活或NF-κB活化的药物。 相关的组合物和方法。

    Change of the Load State of Mhc Molecules
    10.
    发明申请
    Change of the Load State of Mhc Molecules 审中-公开
    改变Mhc分子的负载状态

    公开(公告)号：US20070280957A1

    公开(公告)日：2007-12-06

    申请号：US11663146

    申请日：2005-09-16

    Applicant: Kirsten Falk ,  Olaf Rotzschke

    Inventor： Kirsten Falk ,  Olaf Rotzschke

    IPC: C07K1/113 ,  A61K38/00 ,  G01N33/00 ,  G01N33/566 ,  A61K39/385

    CPC classification number: C07K14/70539 ,  A61K39/385 ,  A61K2039/605 ,  Y02A50/487

    Abstract: The present invention relates to methods for changing the load state of MHC molecules with ligands, the change in the load state being catalysed by a compound of formulae I, IA, II, III or IV1 to IV3. The invention relates further to the use of compounds of formulae I, IA, II, III or IV1 to IV3 or to the use of MHC molecules loaded with ligands, which molecules can be prepared by a method according to the invention, for the treatment of disorders or conditions that are associated with various pathologically excessive or absent immune responses and also for triggering tumour-specific, pathogen-specific or autoreactive immune responses. The invention additionally relates to the use of such compounds for the treatment and diagnosis of cancer, infectious diseases, autoimmune diseases and for attenuating aggressive immune reactions, as well as to the preparation of a vaccine or of a pharmaceutical composition for the treatment of the mentioned disorders or conditions.

    Abstract translation: 本发明涉及用配体改变MHC分子的负载状态的方法，负载状态的变化由式I，IA，II，III或IV1至IV3化合物催化。 本发明进一步涉及式I，IA，II，III或IV1至IV3化合物的用途或使用负载配体的MHC分子，该分子可通过本发明的方法制备，用于治疗 与各种病理过度或不存在的免疫应答相关的疾病或病症，也用于触发肿瘤特异性，病原体特异性或自身反应性免疫应答。 本发明还涉及这些化合物用于治疗和诊断癌症，感染性疾病，自身免疫性疾病和减轻侵袭性免疫反应的用途，以及制备用于治疗上述疾病的疫苗或药物组合物 疾病或病症。

Patent Agency Ranking